KT-110 (New Galenic Form)
Alcohol Use Disorder (AUD)
Formulation TestingUnder evaluation by ANSM
Key Facts
Indication
Alcohol Use Disorder (AUD)
Phase
Formulation Testing
Status
Under evaluation by ANSM
Company
About Kinnov Therapeutics
Kinnov Therapeutics is a private, Phase 3-stage biotech company focused on developing disruptive pharmacological treatments for addiction, including alcohol, tobacco, cocaine, and opioids. Its core innovation is KT-110, a patented combination of two repurposed drugs (prazosin and cyproheptadine) in a novel galenic formulation designed for once-daily dosing. Backed by over 20 years of research, the company has secured support from European funds and key partners, with its Phase 2 results published in the prestigious journal 'Addiction'.
View full company profileTherapeutic Areas
Other Alcohol Use Disorder (AUD) Drugs
| Drug | Company | Phase |
|---|---|---|
| TNX-102 SL | Tonix Pharmaceuticals | Phase 2 (IND Active) |
| KT-110 | Kinnov Therapeutics | Phase 2 |